Back to results
US 2024/0199612 A1Published application
Imidazopyridinyl inhibitors of plasma kallikrein
AssigneeShire Human Genetic Therapies, Inc.
InventorsNikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
Claims30
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein
- CyA is a phenylene or 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyA is substituted with 0-4—RA groups;
- each RA is independently selected from oxo, halogen, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
- each R is independently hydrogen or an optionally substituted C1-6 aliphatic group;
- CyB is selected from phenyl, 8- to 10-membered bicyclic aryl, 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur or 7- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein CyB is substituted with 0-5 —RB groups;
- each RB is independently selected from oxo, halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or a 5- to 6-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
- L is an optionally substituted C1-3 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O—, —NRz—, —S—, —SO—, or —SO2—;
- or L is an optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclene, having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
- each Rz is independently selected from hydrogen, —(CH2)0-3OR, —(CH2)0-3C(O)OR, or an optionally substituted C1-6 aliphatic group;
- X is —O— or —NRy—;
- Ry is hydrogen or an optionally substituted C1-6 aliphatic group;
- L′ is a covalent bond or an optionally substituted C1-3 hydrocarbon chain, wherein a carbon of L′ may optionally be taken together with Ry to form a 3- to 7-membered heterocyclic ring;
- each R3, R4, R5, R6, and R7 is independently selected from hydrogen or -LC-RC, wherein
- each LC is independently selected from a covalent bond or an optionally substituted C1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O— or —NR—;
- each RC is independently selected from halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R, —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, CyC, or an optionally substituted group selected from C1-6 aliphatic;
- each CyC is independently selected from a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, a 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 6- to 12-membered saturated or partially unsaturated fused bicyclic heterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, a bridged bicycle, or a 6- to 12-membered saturated or partially unsaturated bicyclic spiroheterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein CyC is substituted with 0-4 -LD-RD groups;
- each LD is independently selected from a covalent bond or an optionally substituted C1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with —O— or —NR—;
- each RD is independently selected from oxo, halogen, haloalkyl, —CN, —C(O)R, —C(O)2R, —C(O)N(R)2, —NO2, —N(R)2, —N(R)C(O)R, —N(R)C(O)2R, —N(R)S(O)2R,
- —OR, —OC(O)R, —OC(O)N(R)2, —SR, —S(O)R, —S(O)2R, —S(O)N(R)2, —S(O)2N(R)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
- and
- R8 is selected from hydrogen, —OR, or an optionally substituted C1-6 aliphatic group.
18 more elements
Dependencies are inferred from the claim text.